Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Biotechnology
Stocks: MRNA, NVAX

The 3 Best Biotech Stocks to Buy Offer 182% Upside on a Coronavirus Cure

By Money Morning Staff Reports, Money Morning • February 10, 2020

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

The Dow sank 600 points when news of coronavirus first began circulating. Though it's regained some of those losses, the market may still hurt for a time.

However, there are a few biotech stocks charged with seeking out a vaccine that could pop over the next year. In fact, our best biotech stock offers 182% upside potential.

Today, we're sharing our best stocks to buy this year that are working toward a vaccine and expecting a bump in the process.

The White House recently fast-tracked approval for vaccine trials, and we like these three biotech firms as the best chances to find one.

Biotech Stocks to Buy, No. 3: Moderna Inc.

Moderna Inc. (NASDAQ: MRNA) is a Massachusetts-based biotech focused on drug discovery and development.

This company may have developed a potential shortcut to the process of finding a vaccine. It's actually looking at ways to shorten the process of developing vaccines for outbreaks like this in general.

This involves injecting a synthetic messenger RNA in patients that allows the body to develop its own unique defense.

This company is only 10 years old, and its novel approach to fighting cancers and cardiovascular, metabolic, and renal diseases has secured a place on the world stage.

Historic FDA Approval: This biotech just received FDA approval for a first-of-its-kind treatment for a growing health crisis. There’s still time to get in on the biggest gains – if you act fast. Click here to get this FREE pick now.

One of its earliest partnerships was a $24 million deal with the U.S. Defense Advanced Research Projects Agency to develop synthetic RNA technology to fight against biological weapons. Later, Moderna also went on to partner with the Biomedical Advanced Research and Development Authority to develop a Zika vaccine in 2016.

Now, it's working with the National Institute of Allergy and Infectious Diseases toward a coronavirus vaccine.

And it could lead the pack with its unique, speedy approach. Analysts give it a high 12-month target of $40 from today's $19.92. That's a more than 100% profit for investors.

This next stock, however, may have even more to gain...

Biotech Stocks to Buy No. 2: Novavax

Novavax Inc. (NASDAQ: NVAX) may develop a vaccine in three months.

The Maryland-based vaccine company already saw shares rocket 60% as coronavirus fears started to circulate in late January. That's an indication its price could react dramatically if Novavax beats the competition to an effective treatment.

What separates Novavax is that it specializes in vaccines - no fancy gimmicks - most famous for its flu vaccine.

This company is currently putting several different vaccines through clinical trials, and they should produce their late-stage results by the end of Q1 2020.

And Novavax has already developed vaccines for both SARS and MERs. Neither of these were approved in the end, but that doesn't mean the company can't come through on its ambitious three-month goal for the Wuhan virus.

If it is successful, the stock could potentially soar from today's $6.88 to the average analyst target of $13.75 - more than 99% profit for today's investor.

But we have a feeling this next company could produce a successful vaccine even quicker...

The Best Biotech Stock for 182% Profit

Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter

Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…

Claim My Free Report

Subscribe
Login
Notify of
guest

guest

0 Comments
Inline Feedbacks
View all comments


Latest News

September 22, 2023 • By Shah Gilani

earnings
Why the Fed's "Higher for Longer" Message on Interest Rates is Bogus

September 22, 2023 • By Tom Gentile

This is the Top 'Worst-in-Breed' Stock Heading into October

September 21, 2023 • By Shah Gilani

earnings
The Best Auto Stocks to Buy (or Avoid) Right Now
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Penny Hawk Midday Momentum
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Quantum Data Profits Flashpoint Trader Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance L.A.U.N.C.H. Investor Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz